Description: Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.
Home Page: www.crisprtx.com
CRSP Technical Analysis
Baarerstrasse 14
Zug,
6300
Switzerland
Phone:
41 41 561 32 77
Officers
| Name | Title |
|---|---|
| Dr. Samarth Kulkarni Ph.D. | CEO & Director |
| Mr. Brendan Smith M.B.A. | Sr. VP, CFO & Principal Accounting Officer |
| Dr. Lawrence Otto Klein Ph.D. | Chief Operating Officer |
| Mr. James R. Kasinger | Gen. Counsel & Sec. |
| Dr. Rodger Novak M.D. | Founder, Chairman & Pres |
| Mr. Shaun Foy | Founder |
| Dr. Emmanuelle Marie Charpentier | Co-Founder & Scientific Advisory Board Member |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 23.3645 |
|---|---|
| Trailing PE: | 12.4149 |
| Price-to-Book MRQ: | 2.0111 |
| Price-to-Sales TTM: | 253.2571 |
| IPO Date: | 2016-10-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 473 |